Biomarker World Congress

Pre-Conference Events:

Executive ThinkTank: Collaborations, Consortia, and Funding Opportunities in Biomarker Development
Short Course: Fit-for-Purpose Biomarker Assay Development & Validation
Workshop: Biomarkers for Cancer Drug Development

Comprehensive Coverage of Biomarkers in:

• Personalized Medicine
• Clinical Pharmacology
• Translational Medicine
• Molecular Diagnostics
• Safety Assessment
• Clinical Trials
• Assay Development
• Biomarker Qualification
• Oncology Drugs & Diagnostics

• Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery
  Technology Group, GlaxoSmithKline
  
  
• John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
  
  
• Michael E. Burczynski, Ph.D., Associate Director, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals
  
  
• C. Thomas Caskey, M.D., F.A.C.P., Director & Chief Executive Officer, The Brown Foundation Institute of Molecular Medicine and Genetics, The University of Texas, Health Science Center at Houston
  
  
• Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute
  
  
• Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
  
  
• Iman El-Hariry, M.D., Ph.D., Group Director, Oncology MDC, GlaxoSmithKline Research & Development
  
  
• Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.
  
  
• Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research
  
  
• Paul J. Fielder, Ph.D.,  Senior Director & Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences, Genentech, Inc.    
  
  
• Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited
  
  
• Dorothee Foernzler, Ph.D., Biomarker-Experimental Medicine Leader, F. Hoffmann-La Roche AG
  
  
• Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food and Drug Administration
  
  
• Yiwu He, Ph.D., Senior Program Officer, Global Health Discovery, Bill & Melinda Gates Foundation
  
  
• Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA
  
  
• Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, AstraZeneca
  
  
• Martina Kaufmann, Ph.D., Biomarker Project Leader, Early Clinical Development Oncology, Novartis Pharma AG
  
  
• Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.
  
  
• Chetan Lathia, Ph.D., Director, Global Clinical Pharmacology, Bayer Corp.
  
  
• Kwan Lee, Ph.D., Senior Director, Department of Biostatistics and Data Management, GlaxoSmithKline
  
  
• Francois Legay, Ph.D., Global Head, Marker Localization & Assays, Novartis Pharma AG
  
  
• Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
  
  
• Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F. Hoffmann-La Roche AG
  
  
• Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health
  
  
• Patrick Y. Mueller, Ph.D., Project Leader, Safety Assessment, Novartis Pharma AG
  
  
• Matthew R. Nelson, Ph.D., Senior Scientific Investigator, Statistical Genetics Development, GlaxoSmithKline
  
  
• Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
  
  
• Christoph Petry, Ph.D., Head, Molecular Research Germany, Siemens Healthcare Diagnostics Products GmbH
  
  
• Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration
  
  
• Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals     
  
  
• Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs
  
  
• Linda C. Surh, M.D., Ph.D., FRCPC, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK
  
  
• Ole Vesterqvist, Ph.D., Senior Director, Biomarker Lab & Outsourcing, Clinical Translational Medicine, Wyeth Research
  
  
• Xinkang Wang, Ph.D., Head, Imaging Biomarker Group, Discovery Translational Medicine, Wyeth Research
  
  
• Jeffrey Waring, Ph.D., Associate Research Fellow & Group Leader, Cellular & Molecular Toxicology, Abbott Labs
  
  
• David Wholley, Director, Biomarkers Consortium, Foundation for the National Institutes of Health
  
  
• Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson